The efficacy and safety of iGlarLixi versus IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drugs: The Soli‐D randomized controlled trial
In Chinese people with T2D suboptimally controlled with OADs, once-daily iGlarLixi provided better glycaemic control with BW benefit and lower hypoglycaemia event rates versus IDegAsp.
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
cdercder
大力的冬萱
Copyright
liuzhuohao
Nole
行走的荷尔蒙
ale
arniu2008
OK
Avalonx
sanvva
认真的不评
无情的聪健
初景
Oracle
lizishu
昏睡的蟠桃
学术文献互助
pluto
皖公网安备34019202002308
